TY - JOUR
T1 - Neoadjuvant chemotherapy and less invasive surgery for the management of early stage cervical cancer
T2 - A brief report from Botswana
AU - Grover, Surbhi
AU - Luckett, Rebecca
AU - Bhatia, Rohini K.
AU - Ralefala, Tlotlo
AU - Seiphetlheng, Alexander
AU - Ramogola-Masire, Doreen
AU - Monare, Barati
AU - Bazzett-Matabele, Lisa
AU - Schmeler, Kathleen
AU - Gaolebale, Ponatshego Andrew
N1 - Publisher Copyright:
© 2022
PY - 2022/8
Y1 - 2022/8
N2 - The majority of deaths from cervical cancer occur in low- and middle- income countries (LMICs). The standard of care for early-stage cervical cancer (FIGO 2018 IA2-IB1) is radical hysterectomy, a procedure performed by trained gynecologic oncologists. However, the lack of gynecologic oncologists in LMICs has required exploration into other methods of treatment for early-stage cervical cancer. A potential course of treatment for early-stage cervical cancer is neoadjuvant chemotherapy followed by simple hysterectomy and pelvic lymph node sampling, which can be performed by a general gynecologist. We gathered data for 8 women who underwent this method of treatment and found that cause-specific survival was 100% over a 3.5-year median follow-up. These findings support the exploration for this method of treatment for early-stage cervical cancer in LMICs, which would improve access to treatment for these women and hopefully reduce the high burden of cervical cancer related deaths in LMICs.
AB - The majority of deaths from cervical cancer occur in low- and middle- income countries (LMICs). The standard of care for early-stage cervical cancer (FIGO 2018 IA2-IB1) is radical hysterectomy, a procedure performed by trained gynecologic oncologists. However, the lack of gynecologic oncologists in LMICs has required exploration into other methods of treatment for early-stage cervical cancer. A potential course of treatment for early-stage cervical cancer is neoadjuvant chemotherapy followed by simple hysterectomy and pelvic lymph node sampling, which can be performed by a general gynecologist. We gathered data for 8 women who underwent this method of treatment and found that cause-specific survival was 100% over a 3.5-year median follow-up. These findings support the exploration for this method of treatment for early-stage cervical cancer in LMICs, which would improve access to treatment for these women and hopefully reduce the high burden of cervical cancer related deaths in LMICs.
KW - Cervical cancer
KW - Hysterectomy
KW - LMICs
KW - Neoadjuvant chemotherapy
UR - http://www.scopus.com/inward/record.url?scp=85132922001&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85132922001&partnerID=8YFLogxK
U2 - 10.1016/j.gore.2022.101032
DO - 10.1016/j.gore.2022.101032
M3 - Article
C2 - 35782102
AN - SCOPUS:85132922001
SN - 2211-338X
VL - 42
JO - Gynecologic Oncology Reports
JF - Gynecologic Oncology Reports
M1 - 101032
ER -